MA51649A - Culture de placenta pour isoler des exosomes - Google Patents

Culture de placenta pour isoler des exosomes

Info

Publication number
MA51649A
MA51649A MA051649A MA51649A MA51649A MA 51649 A MA51649 A MA 51649A MA 051649 A MA051649 A MA 051649A MA 51649 A MA51649 A MA 51649A MA 51649 A MA51649 A MA 51649A
Authority
MA
Morocco
Prior art keywords
placenta
cultivation
isolate exosomes
exosomes
isolate
Prior art date
Application number
MA051649A
Other languages
English (en)
Inventor
Qian Ye
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of MA51649A publication Critical patent/MA51649A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
MA051649A 2017-11-16 2018-11-16 Culture de placenta pour isoler des exosomes MA51649A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587335P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
MA51649A true MA51649A (fr) 2020-09-23

Family

ID=65279618

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051649A MA51649A (fr) 2017-11-16 2018-11-16 Culture de placenta pour isoler des exosomes

Country Status (13)

Country Link
US (2) US20190307686A1 (fr)
EP (1) EP3710575A1 (fr)
JP (2) JP2021503301A (fr)
KR (1) KR20200083596A (fr)
CN (1) CN111433352A (fr)
AU (1) AU2018370157A1 (fr)
CA (1) CA3082880A1 (fr)
EA (1) EA202091219A1 (fr)
MA (1) MA51649A (fr)
MX (1) MX2020005100A (fr)
PH (1) PH12020550660A1 (fr)
SG (1) SG11202004523SA (fr)
WO (1) WO2019099955A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538004A (ja) * 2019-06-19 2022-08-31 セルラリティ インク． 疾患治療用エキソソーム
KR102615824B1 (ko) * 2020-03-18 2023-12-21 가톨릭대학교 산학협력단 제대혈 혈장 엑소좀 모방체 제작 및 이의 상처치료 용도
WO2021209622A1 (fr) * 2020-04-17 2021-10-21 Therawis Diagnostics Gmbh Procédé pour enrichir des exosomes
WO2021216903A1 (fr) * 2020-04-22 2021-10-28 Kenneth Allen Pettine Procédés et compositions de traitement d'états inflammatoires associés à une maladie infectieuse
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
TW202146034A (zh) * 2020-05-05 2021-12-16 美國商加速生物科學有限公司 包含有分泌蛋白體的藥學與化妝品組成物
KR102316777B1 (ko) * 2020-06-26 2021-10-25 주식회사 씨케이엑소젠 엑소좀 생산 조절 세포, 이를 포함하는 조성물, 이로부터 얻은 엑소좀 및 엑소좀 생산 방법
CN112903999A (zh) * 2021-01-20 2021-06-04 蚌埠医学院第一附属医院（蚌埠医学院附属肿瘤医院） 一种用于纳米流式细胞仪检测的外泌体的制备方法及应用
JP7044429B1 (ja) * 2021-12-20 2022-03-30 株式会社 バイオミメティクスシンパシーズ 腫瘍を縮小、又は消失させるための組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687219A1 (fr) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Utilisation de préparations contenant des exosomes dérivées de cellules souches mésenchymateuses (msc) dans la prévention et le traitement d'états inflammatoires
AU2015330855A1 (en) * 2014-10-09 2017-04-27 Celularity Inc. Placenta-derived adherent cell exosomes and uses thereof
CN106282107A (zh) * 2016-08-30 2017-01-04 章毅 人胎盘间充质干细胞源分离外泌体的方法及其应用

Also Published As

Publication number Publication date
JP2021503301A (ja) 2021-02-12
KR20200083596A (ko) 2020-07-08
CN111433352A (zh) 2020-07-17
WO2019099955A1 (fr) 2019-05-23
EP3710575A1 (fr) 2020-09-23
CA3082880A1 (fr) 2019-05-23
US20230310319A1 (en) 2023-10-05
EA202091219A1 (ru) 2020-08-18
MX2020005100A (es) 2020-11-24
PH12020550660A1 (en) 2021-04-26
AU2018370157A1 (en) 2020-05-28
JP2024023185A (ja) 2024-02-21
SG11202004523SA (en) 2020-06-29
US20190307686A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
MA51649A (fr) Culture de placenta pour isoler des exosomes
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
DK3209691T3 (da) Sammensætninger til inducering af differentiering af myeloid-afledt suppresorcelle til behandling af cancer og infektiøse sygdomme
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA40872A (fr) Méthodes pour la préparation de ribosides
FR3021533B1 (fr) Composition cosmetique de type gel
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
MA41449A (fr) Polythérapies pour le traitement de cancers
BR112017009540A2 (pt) biorreator usando macroalgas
FR3013222B1 (fr) Extrait d'algues pour son utilisation en tant qu'agent immunomodulateur
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
IT201600100016A1 (it) Composizione di coloranti per capelli
GB201506541D0 (en) Improved methods for cryopreservation of biological materials
FR3015285B1 (fr) Formulation pour le traitement des cheveux
FR3055892B1 (fr) Materiau silicate de structure olivine
FR3013223B1 (fr) Extrait d'algues pour son utilisation en tant qu'agent anti-bacterien
DE112016002764A5 (de) System zur Beeinflussung der Homöostase biologischer Objekte
CL2016001959A1 (es) Hexahidrofuropirroles como inhibidores de pde1
FI20155958A (fi) Maidon mineraalikoostumuksen muokkaaminen
FR3025098B1 (fr) Composition cosmetique de type gel facilement demaquillable
FR3024425B1 (fr) Ensemble de chariots configure pour etre remorque
FR3024647B1 (fr) Transat de puericulture
MA51688A (fr) Protéines prohémostatiques pour le traitement de saignement
BR112017025694A2 (pt) produção biotecnológica de ésteres de vetiveril